Laboratorios Farmaceuticos Rovi Stock Price To Earnings To Growth
| ROVI Stock | EUR 54.35 0.95 1.72% |
Laboratorios Farmaceuticos ROVI fundamentals help investors to digest information that contributes to Laboratorios Farmaceuticos' financial success or failures. It also enables traders to predict the movement of Laboratorios Stock. The fundamental analysis module provides a way to measure Laboratorios Farmaceuticos' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Laboratorios Farmaceuticos stock.
Laboratorios |
Laboratorios Farmaceuticos ROVI Company Price To Earnings To Growth Analysis
Laboratorios Farmaceuticos' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Laboratorios Farmaceuticos Price To Earnings To Growth | 3.17 X |
Most of Laboratorios Farmaceuticos' fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Laboratorios Farmaceuticos ROVI is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Laboratorios Farmaceuticos ROVI has a Price To Earnings To Growth of 3.17 times. This is 346.48% higher than that of the Pharmaceuticals sector and about the same as Health Care (which currently averages 3.14) industry. The price to earnings to growth for all Spain stocks is 35.17% higher than that of the company.
Laboratorios Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Laboratorios Farmaceuticos' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Laboratorios Farmaceuticos could also be used in its relative valuation, which is a method of valuing Laboratorios Farmaceuticos by comparing valuation metrics of similar companies.Laboratorios Farmaceuticos is currently under evaluation in price to earnings to growth category among its peers.
Laboratorios Fundamentals
| Return On Equity | 0.39 | |||
| Return On Asset | 0.18 | |||
| Profit Margin | 0.23 % | |||
| Operating Margin | 0.28 % | |||
| Current Valuation | 1.93 B | |||
| Shares Outstanding | 51.32 M | |||
| Shares Owned By Insiders | 60.25 % | |||
| Shares Owned By Institutions | 17.88 % | |||
| Price To Earning | 43.87 X | |||
| Price To Book | 4.42 X | |||
| Price To Sales | 2.54 X | |||
| Revenue | 648.68 M | |||
| Gross Profit | 379.83 M | |||
| EBITDA | 204.66 M | |||
| Net Income | 182.63 M | |||
| Cash And Equivalents | 126.82 M | |||
| Cash Per Share | 2.26 X | |||
| Total Debt | 52.52 M | |||
| Debt To Equity | 0.18 % | |||
| Current Ratio | 2.62 X | |||
| Book Value Per Share | 8.28 X | |||
| Cash Flow From Operations | 149.44 M | |||
| Earnings Per Share | 3.33 X | |||
| Price To Earnings To Growth | 3.17 X | |||
| Target Price | 68.09 | |||
| Number Of Employees | 1.75 K | |||
| Beta | 0.47 | |||
| Market Capitalization | 2.1 B | |||
| Total Asset | 732.68 M | |||
| Z Score | 23.4 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 0.87 % | |||
| Net Asset | 732.68 M |
About Laboratorios Farmaceuticos Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Laboratorios Farmaceuticos ROVI's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Laboratorios Farmaceuticos using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Laboratorios Farmaceuticos ROVI based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Laboratorios Stock
Laboratorios Farmaceuticos financial ratios help investors to determine whether Laboratorios Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Laboratorios with respect to the benefits of owning Laboratorios Farmaceuticos security.